Immuneel Therapeutics, a Bengaluru-based clinical-stage biotech focused on cell and gene therapies, has announced a strategic collaboration with Manas AI, an India-based AI company specializing in life sciences. The partnership brings cutting-edge artificial intelligence directly into Immuneel’s drug discovery and development engine, with the goal of accelerating innovation in immuno-oncology and beyond.

Manas AI provides proprietary large language models and multimodal AI systems trained specifically on biological and chemical data. These tools enable rapid analysis of omics datasets, protein interactions, pathway modeling, and predictive simulations capabilities that can dramatically reduce the time and cost of early-stage discovery. Immuneel will apply this technology to refine target validation, improve CAR construct design, enhance safety profiling, and prioritize the most promising candidates for IND submission.

The collaboration is particularly relevant for Immuneel’s lead programs in autologous and allogeneic CAR-T therapies, where precision in target selection and construct optimization is critical for efficacy and safety. By combining Manas AI’s computational power with Immuneel’s deep clinical and manufacturing experience, the partners aim to create a more efficient, data-driven pipeline that can respond quickly to emerging scientific insights.

This alliance reflects the growing momentum of AI-native drug discovery in India. Both companies emphasized that the partnership will remain deeply rooted in India’s biotech ecosystem while positioning their technologies for global impact, especially in addressing high-unmet-need cancers and immune disorders.